CGM monitoring for weeks
2018: FDA approves the Eversense CGM system
The Eversense CGM from Senseonics provides glucose data every five minutes for up to 90 days via an implantable sensor. A transmitter and mobile app round out the system. The company’s Eversense XL system, which has a 180-day lifespan, is awaiting FDA approval.
2020: FreeStyle Libre 2 wins FDA clearance
Abbott’s FreeStyle Libre 2, which was introduced in the U.S. in 2020, is an integrated continuous glucose monitor rather than a flash glucose monitor. It notifies users when glucose levels are high or low without requiring them to scan the device. The device is the first patient-facing CGM to have a 14-day lifespan.